NCT06989112
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06989112 |
| Title | DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer (DE-01) |
| Acronym | DE-01 |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | AstraZeneca |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | USA | SWE | POL | NOR | NLD | ITA | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUT | AUS |
CKB BOOST